The DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
Immunotherapy for hepatocellular carcinoma
Open accessAbstract
Despite significant research efforts, only a few treatment approaches have been developed for hepatocellular carcinoma (HCC). In recent years, immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies) have exhibited potential therapeutic effects for advanced HCC. With the development of gene-editing technologies, gene-sequencing technologies, big data strategies, and artificial intelligence algorithms, engineered immune cell infusion and personalized cancer vaccine therapy have emerged as important directions for anti-HCC treatment. Combining different immunotherapies or combining immunotherapies with conventional therapeutic approaches may provide synergistic effects and facilitate the development of personalized medicine. In this study, we provide an overview of the liver immunoanatomy, the potential immune mechanisms of HCC, and current (pre)clinical developments in this field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Jiang, C., Liu, X., Wang, M., Lv, G., & Wang, G. (2019) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504018x15456687424096 · Cited by 18
RetractedBray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,653
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490
Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
Hepatic stellate cells as key target in liver fibrosis
Higashi, T., Friedman, S. L., & Hoshida, Y. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.007 · Cited by 1,485
Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics
Cronin, K. A., Lake, A. J., Scott, S., Sherman, R. L., Noone, A., Howlader, N., Henley, S. J., Anderson, R. N., Firth, A. U., Ma, J., et al. (2018) · Cancer · doi:10.1002/cncr.31551 · Cited by 1,485
The Liver as an Immunological Organ
Racanelli, V., & Rehermann, B. (2006) · Hepatology · doi:10.1002/hep.21060 · Cited by 1,377
Immunology in the liver — from homeostasis to disease
Heymann, F., & Tacke, F. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.200 · Cited by 1,180
Personalized vaccines for cancer immunotherapy
Sahin, U., & Türeci, Ö. (2018) · Science · doi:10.1126/science.aar7112 · Cited by 1,147
Towards personalized, tumour-specific, therapeutic vaccines for cancer
Hu, Z., Ott, P. A., & Wu, C. J. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.131 · Cited by 1,067
Immune surveillance by the liver
Jenne, C. N., & Kubes, P. (2013) · Nature Immunology · doi:10.1038/ni.2691 · Cited by 1,047
Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions
Brennan, P. J., Brigl, M., & Brenner, M. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3369 · Cited by 835
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
Duffy, A. G., Ulahannan, S. V., Makorova-Rusher, O., Rahma, O., Wedemeyer, H., Pratt, D., Davis, J. L., Hughes, M. S., Heller, T., ElGindi, M., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.10.029 · Cited by 819
Antigen-presenting cell function in the tolerogenic liver environment
Thomson, A. W., & Knolle, P. A. (2010) · Nature Reviews Immunology · doi:10.1038/nri2858 · Cited by 805
Limmer, A., Ohl, J., Kurts, C., Ljunggren, H.-G., Reiss, Y., Groettrup, M., Momburg, F., Arnold, B., & Knolle, P. A. (2000) · Nature Medicine · doi:10.1038/82161 · Cited by 758
History, Heterogeneity, Developmental Biology, and Functions of Quiescent Hepatic Stellate Cells
Geerts, A. (2001) · Seminars in Liver Disease · doi:10.1055/s-2001-17550 · Cited by 740
Wisse, E., de Zanger, R. B., Charels, K., van der Smissen, P., & McCuskey, R. S. (1985) · Hepatology · doi:10.1002/hep.1840050427 · Cited by 712
CRIg: A Macrophage Complement Receptor Required for Phagocytosis of Circulating Pathogens
Helmy, K. Y., Katschke, K. J., Gorgani, N. N., Kljavin, N. M., Elliott, J. M., Diehl, L., Scales, S. J., Ghilardi, N., & van Lookeren Campagne, M. (2006) · Cell · doi:10.1016/j.cell.2005.12.039 · Cited by 628
Immunological landscape and immunotherapy of hepatocellular carcinoma
Prieto, J., Melero, I., & Sangro, B. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.173 · Cited by 566
Monteiro, R. C., & van de Winkel, J. G. J. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141011 · Cited by 531
Chen, Y., Ramjiawan, R. R., Reiberger, T., Ng, M. R., Hato, T., Huang, Y., Ochiai, H., Kitahara, S., Unan, E. C., Reddy, T. P., et al. (2015) · Hepatology · doi:10.1002/hep.27665 · Cited by 451
Activation of Hepatic Stem Cell Marker EpCAM by Wnt–β-Catenin Signaling in Hepatocellular Carcinoma
Yamashita, T., Budhu, A., Forgues, M., & Wang, X. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0908 · Cited by 446
Calderaro, J., Rousseau, B., Amaddeo, G., Mercey, M., Charpy, C., Costentin, C., Luciani, A., Zafrani, E., Laurent, A., Azoulay, D., et al. (2016) · Hepatology · doi:10.1002/hep.28710 · Cited by 440
Zhou, G., Sprengers, D., Boor, P. P. C., Doukas, M., Schutz, H., Mancham, S., Pedroza-Gonzalez, A., Polak, W. G., de Jonge, J., Gaspersz, M., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.017 · Cited by 412
CD1d-restricted iNKT cells, the ‘Swiss-Army knife’ of the immune system
Matsuda, J. L., Mallevaey, T., Scott-Browne, J., & Gapin, L. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.03.018 · Cited by 407
Liver inflammation abrogates immunological tolerance induced by Kupffer cells
Heymann, F., Peusquens, J., Ludwig‐Portugall, I., Kohlhepp, M., Ergen, C., Niemietz, P., Martin, C., van Rooijen, N., Ochando, J. C., Randolph, G. J., et al. (2015) · Hepatology · doi:10.1002/hep.27793 · Cited by 398
Immune checkpoint therapy in liver cancer
Xu, F., Jin, T., Zhu, Y., & Dai, C. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0777-4 · Cited by 397
Katz, S. C., Burga, R. A., McCormack, E., Wang, L. J., Mooring, W., Point, G. R., Khare, P. D., Thorn, M., Ma, Q., Stainken, B. F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1421 · Cited by 394
Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma
Long, J., Wang, A., Bai, Y., Lin, J., Yang, X., Wang, D., Yang, X., Jiang, Y., & Zhao, H. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.022 · Cited by 380
Lim, C. J., Lee, Y. H., Pan, L., Lai, L., Chua, C., Wasser, M., Lim, T. K. H., Yeong, J., Toh, H. C., Lee, S. Y., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316510 · Cited by 357
An intravascular immune response to Borrelia burgdorferi involves Kupffer cells and iNKT cells
Lee, W.-Y., Moriarty, T. J., Wong, C. H. Y., Zhou, H., Strieter, R. M., van Rooijen, N., Chaconas, G., & Kubes, P. (2010) · Nature Immunology · doi:10.1038/ni.1855 · Cited by 355
Warren, A., Le Couteur, D. G., Fraser, R., Bowen, D. G., McCaughan, G. W., & Bertolino, P. (2006) · Hepatology · doi:10.1002/hep.21378 · Cited by 347
Kimura, T., Kato, Y., Ozawa, Y., Kodama, K., Ito, J., Ichikawa, K., Yamada, K., Hori, Y., Tabata, K., Takase, K., et al. (2018) · Cancer Science · doi:10.1111/cas.13806 · Cited by 336
Hepatocellular carcinoma (HCC): beyond sorafenib—chemotherapy
Kim, D. W., Talati, C., & Kim, R. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.09.07 · Cited by 333
Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma
Gao, H., Li, K., Tu, H., Pan, X., Jiang, H., Shi, B., Kong, J., Wang, H., Yang, S., Gu, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1170 · Cited by 313
PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells
West, E. E., Jin, H.-T., Rasheed, A.-U., Penaloza-MacMaster, P., Ha, S.-J., Tan, W. G., Youngblood, B., Freeman, G. J., Smith, K. A., & Ahmed, R. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67008 · Cited by 298
Horst, A. K., Neumann, K., Diehl, L., & Tiegs, G. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.112 · Cited by 295
The yin and yang of evasion and immune activation in HCC
Makarova-Rusher, O. V., Medina-Echeverz, J., Duffy, A. G., & Greten, T. F. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.038 · Cited by 293
Diehl, L., Schurich, A., Grochtmann, R., Hegenbarth, S., Chen, L., & Knolle, P. A. (2008) · Hepatology · doi:10.1002/hep.21965 · Cited by 291
Therapeutic Cancer Vaccines: Current Status and Moving Forward
Schlom, J. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs033 · Cited by 282
Mizukoshi, E., Yamashita, T., Arai, K., Sunagozaka, H., Ueda, T., Arihara, F., Kagaya, T., Yamashita, T., Fushimi, K., & Kaneko, S. (2013) · Hepatology · doi:10.1002/hep.26153 · Cited by 273
Kalathil, S., Lugade, A. A., Miller, A., Iyer, R., & Thanavala, Y. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3381 · Cited by 271
Hepatocellular Carcinoma: Etiology and Current and Future Drugs
Jindal, A., Thadi, A., & Shailubhai, K. (2019) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2019.01.004 · Cited by 257
Matsuno, K., Ezaki, T., Kudo, S., & Uehara, Y. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.4.1865 · Cited by 254
Treg-mediated acquired resistance to immune checkpoint inhibitors
Saleh, R., & Elkord, E. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.003 · Cited by 236
The scavenger endothelial cell: a new player in homeostasis and immunity
Sørensen, K. K., McCourt, P., Berg, T., Crossley, C., Couteur, D. L., Wake, K., & Smedsrød, B. (2012) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00686.2011 · Cited by 233
The role of Kupffer cells in hepatic diseases
Li, P., He, K., Li, J., Liu, Z., & Gong, J. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.02.018 · Cited by 233
Pillarisetty, V. G., Shah, A. B., Miller, G., Bleier, J. I., & DeMatteo, R. P. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.2.1009 · Cited by 232
Targeting Alpha-Fetoprotein (AFP)–MHC Complex with CAR T-Cell Therapy for Liver Cancer
Liu, H., Xu, Y., Xiang, J., Long, L., Green, S., Yang, Z., Zimdahl, B., Lu, J., Cheng, N., Horan, L. H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1203 · Cited by 231
Burga, R. A., Thorn, M., Point, G. R., Guha, P., Nguyen, C. T., Licata, L. A., DeMatteo, R. P., Ayala, A., Joseph Espat, N., Junghans, R. P., et al. (2015) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-015-1692-6 · Cited by 230
Bacteria in the bloodstream are trapped in the liver and killed by immigrating neutrophils
Gregory, S. H., Sagnimeni, A. J., & Wing, E. J. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.6.2514 · Cited by 218
Jiang, Z., Jiang, X., Chen, S., Lai, Y., Wei, X., Li, B., Lin, S., Wang, S., Wu, Q., Liang, Q., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00690 · Cited by 207
An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors
Ishiguro, T., Sano, Y., Komatsu, S.-I., Kamata-Sakurai, M., Kaneko, A., Kinoshita, Y., Shiraiwa, H., Azuma, Y., Tsunenari, T., Kayukawa, Y., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal4291 · Cited by 207
Guo, X., Jiang, H., Shi, B., Zhou, M., Zhang, H., Shi, Z., Du, G., Luo, H., Wu, X., Wang, Y., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01118 · Cited by 206
Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials
Kudo, M. (2017) · Oncology · doi:10.1159/000451016 · Cited by 194
Li, H., Li, X., Liu, S., Guo, L., Zhang, B., Zhang, J., & Ye, Q. (2017) · Hepatology · doi:10.1002/hep.29360 · Cited by 194
Bogdanos, D. P., Gao, B., & Gershwin, M. E. (2013) · Comprehensive Physiology · doi:10.1002/cphy.c120011 · Cited by 185
Expression of class I and class II major histocompatibility complex antigens on human hepatocytes
Franco, A., Barnaba, V., Natali, P., Balsano, C., Musca, A., & Balsano, F. (1988) · Hepatology · doi:10.1002/hep.1840080302 · Cited by 184
MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1
Li, H., Li, C.-W., Li, X., Ding, Q., Guo, L., Liu, S., Liu, C., Lai, C.-C., Hsu, J.-M., Dong, Q., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.252 · Cited by 182
Duan, M., Goswami, S., Shi, J.-Y., Wu, L.-J., Wang, X.-Y., Ma, J.-Q., Zhang, Z., Shi, Y., Ma, L.-J., Zhang, S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3040 · Cited by 181
Greten, T. F., Wang, X. W., & Korangy, F. (2015) · Gut · doi:10.1136/gutjnl-2014-307990 · Cited by 176
Systemic Therapy for Hepatocellular Carcinoma: Latest Advances
Kudo, M. (2018) · Cancers · doi:10.3390/cancers10110412 · Cited by 172
Chen, D.-P., Ning, W.-R., Jiang, Z.-Z., Peng, Z.-P., Zhu, L.-Y., Zhuang, S.-M., Kuang, D.-M., Zheng, L., & Wu, Y. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.007 · Cited by 170
Rationally Combining Anti-VEGF Therapy with Checkpoint Inhibitors in Hepatocellular Carcinoma
Hato, T., Zhu, A. X., & Duda, D. G. (2016) · Immunotherapy · doi:10.2217/imt.15.126 · Cited by 159
DeLeon, T. T., Salomao, M. A., Aqel, B. A., Sonbol, M. B., Yokoda, R. T., Ali, A. H., Moss, A. A., Mathur, A. K., Chascsa, D. M., Rakela, J., et al. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.07.05 · Cited by 157
Agdashian, D., ElGindi, M., Xie, C., Sandhu, M., Pratt, D. W., Kleiner, D. E., Figg, W. D., Rytlewski, J. A., Sanders, C. M., Yusko, E. C., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02299-8 · Cited by 154
Pillarisetty, V. G., Katz, S. C., Bleier, J. I. S., Shah, A. B., & DeMatteo, R. P. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.5.2612 · Cited by 153
Qin, S., Finn, R. S., Kudo, M., Meyer, T., Vogel, A., Ducreux, M. P., Macarulla, T. M., Tomasello, G., Boisserie, F., Hou, J. W.-S., et al. (2019) · Future Oncology · doi:10.2217/fon-2019-0097 · Cited by 149
Wang, X., Shen, H., Zhangyuan, G., Huang, R., Zhang, W., He, Q., Jin, K., Zhuo, H., Zhang, Z., Wang, J., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0180-7 · Cited by 146
Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan
Kudo, M., Izumi, N., Sakamoto, M., Matsuyama, Y., Ichida, T., Nakashima, O., Matsui, O., Ku, Y., Kokudo, N., Makuuchi, M., et al. (2016) · Liver Cancer · doi:10.1159/000367775 · Cited by 143
Llópiz, D., Ruiz, M., Villanueva, L., Iglesias, T., Silva, L., Egea, J., Lasarte, J. J., Pivette, P., Trochon-Joseph, V., Vasseur, B., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2283-0 · Cited by 141
Liu, P., Chen, L., & Zhang, H. (2018) · Journal of Immunology Research · doi:10.1155/2018/1206737 · Cited by 140
Glypican‐3‐Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma
Fu, Y., Urban, D. J., Nani, R. R., Zhang, Y., Li, N., Fu, H., Shah, H., Gorka, A. P., Guha, R., Chen, L., et al. (2018) · Hepatology · doi:10.1002/hep.30326 · Cited by 138
Friend, B. D., Venick, R. S., McDiarmid, S. V., Zhou, X., Naini, B. V., Wang, H., Farmer, D. G., Busuttil, R. W., & Federman, N. C. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26682 · Cited by 135
Chen, M., Yan, B., Lu, W., Chen, M., Yu, S., Yang, P., & Ann‐Lii, C. (2013) · International Journal of Cancer · doi:10.1002/ijc.28362 · Cited by 130
iNKT Cells Orchestrate a Switch from Inflammation to Resolution of Sterile Liver Injury
Liew, P. X., Lee, W.-Y., & Kubes, P. (2017) · Immunity · doi:10.1016/j.immuni.2017.09.016 · Cited by 125
Chang, B., Huang, T., Wei, H., Shen, L., Zhu, D., He, W., Chen, Q., Zhang, H., Li, Y., Huang, R., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2271-4 · Cited by 125
Brown, Z. J., Yu, S. J., Heinrich, B., Ma, C., Fu, Q., Sandhu, M., Agdashian, D., Zhang, Q., Korangy, F., & Greten, T. F. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2190-4 · Cited by 122
Liver sinusoidal endothelial cells veto CD8 T cell activation by antigen‐presenting dendritic cells
Schildberg, F. A., Hegenbarth, S. I., Schumak, B., Limmer, A., & Knolle, P. A. (2008) · European Journal of Immunology · doi:10.1002/eji.200738060 · Cited by 115
Hepatocellular carcinoma treatment: hurdles, advances and prospects
Kumari, R., V, Sahu, M. K., Tripathy, A., Uthansingh, K., & Behera, M. K. (2018) · Hepatic Oncology · doi:10.2217/hep-2018-0002 · Cited by 115
Adaptive immunity in the liver
Shuai, Z., Leung, M. W., He, X.-S., Zhang, W., Yang, G., Leung, P. S. C., & Gershwin, M. E. (2016) · Cellular and Molecular Immunology · doi:10.1038/cmi.2016.4 · Cited by 113
Pinato, D. J., Mauri, F. A., Spina, P., Cain, L., Siddique, A., Goldin, R. D., Victor, S., Pizio, C., Akarca, A. U., Boldorini, R. L., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0466-x · Cited by 112
Ouyang, F., Wu, R., Yuan, W., Liu, R., Yang, D., Xiao, C., Zheng, L., Li, B., Lao, X., & Kuang, D. (2016) · Nature Communications · doi:10.1038/ncomms13453 · Cited by 109
Use of checkpoint inhibitors in liver transplant recipients
Munker, S., & Toni, E. N. D. (2018) · United European Gastroenterology Journal · doi:10.1177/2050640618774631 · Cited by 109
Hepatic stellate cells secreting WFA + ‐M2BP: Its role in biological interactions with Kupffer cells
Bekki, Y., Yoshizumi, T., Shimoda, S., Itoh, S., Harimoto, N., Ikegami, T., Kuno, A., Narimatsu, H., Shirabe, K., & Maehara, Y. (2016) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13708 · Cited by 106
Zhu, L., Li, N., Li, F., Zhou, Z.-H., Sang, J., Chen, Y., Han, Q., Lv, Y., & Liu, Z. (2016) · Medicine · doi:10.1097/md.0000000000005749 · Cited by 103
Recent developments with immunotherapy for hepatocellular carcinoma
Waidmann, O. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1499722 · Cited by 103
Wada, S., Tsunoda, T., Baba, T., Primus, F. J., Kuwano, H., Shibuya, M., & Tahara, H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3759 · Cited by 102
STAT3 Mediates Regorafenib-Induced Apoptosis in Hepatocellular Carcinoma
Tai, W., Chu, P., Shiau, C., Chen, Y., Li, Y.-S., Hung, M., Chen, L., Chen, P., Su, J., Lin, P., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0725 · Cited by 101
Chen, C., Li, K., Jiang, H., Song, F., Gao, H., Pan, X., Shi, B., Bi, Y., Wang, H., Wang, H., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1949-8 · Cited by 100
Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update
Kudo, M. (2017) · Oncology · doi:10.1159/000481245 · Cited by 100
Trivedi, P. J., & Adams, D. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.12.002 · Cited by 99
Flynn, M. J., Sayed, A. A., Sharma, R., Siddique, A., & Pinato, D. J. (2018) · Hepatology · doi:10.1002/hep.30337 · Cited by 98
Xie, K., Xu, L., Wu, H., Liao, H., Luo, L., Liao, M., Gong, J., Deng, Y., Yuan, K., Wu, H. M., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1404214 · Cited by 96
Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
Pang, Y., Hou, X., Yang, C., Liu, Y., & Jiang, G. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0840-y · Cited by 96
The liver works as a school to educate regulatory immune cells
Li, F., & Tian, Z. (2013) · Cellular and Molecular Immunology · doi:10.1038/cmi.2013.7 · Cited by 95
Immunotherapy for hepatocellular carcinoma: current status and future perspectives
Okusaka, T., & Ikeda, M. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000455 · Cited by 90
Starring stellate cells in liver immunology
Winau, F., Breunig, C., Darmoise, A., & Kaufmann, S. H. E. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.10.006 · Cited by 88
Advances in bispecific biotherapeutics for the treatment of cancer
May, C., Sapra, P., & Gerber, H. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.07.011 · Cited by 87
B7-H1–expressing antigen-presenting cells mediate polarization of protumorigenic Th22 subsets
Kuang, D., Xiao, C., Zhao, Q., Chen, M., Li, X., Liu, R., Yuan, W., Ouyang, F., Chen, D., Wu, Y., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74381 · Cited by 85
Immune Regulation by T Regulatory Cells in Hepatitis B Virus‐Related Inflammation and Cancer
Trehanpati, N., & Vyas, A. K. (2017) · Scandinavian Journal of Immunology · doi:10.1111/sji.12524 · Cited by 85
Chimeric antigen receptor-engineered T-cell therapy for liver cancer
Yang, C., Changyong, E., Gong, Z.-W., Liu, S., Wang, Z., Yang, Y., & Zhang, X. (2018) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2018.05.005 · Cited by 85
Sawada, Y., Yoshikawa, T., Shimomura, M., Iwama, T., Endo, I., & Nakatsura, T. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2737 · Cited by 82
Ishizaki, H., Tsunoda, T., Wada, S., Yamauchi, M., Shibuya, M., & Tahara, H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0750 · Cited by 79
Hu, Z., Luo, D., Wang, D., Ma, L., Zhao, Y., & Li, L. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000484390 · Cited by 76
Novel potential inhibitors of complement system and their roles in complement regulation and beyond
Gialeli, C., Gungor, B., & Blom, A. M. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.05.023 · Cited by 76
Chen, Z., Diaz, G., Pollicino, T., Zhao, H., Engle, R. E., Schuck, P., Shen, C., Zamboni, F., Long, Z., Kabát, J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1809028115 · Cited by 76
Correlation Between PD-L2 Expression and Clinical Outcome in Solid Cancer Patients: A Meta-Analysis
Yang, H., Zhou, X., Sun, L., & Mao, Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00047 · Cited by 75
Semaan, A., Dietrich, D., Bergheim, D., Dietrich, J., Kalff, J. C., Branchi, V., Matthaei, H., Kristiansen, G., Fischer, H., & Goltz, D. (2016) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-016-2051-5 · Cited by 73
Shi, S., Rao, Q., Zhang, C., Zhang, X., Qin, Y., & Niu, Z. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.01.001 · Cited by 73
Zabala, M., Lasarte, J. J., Perret, C., Sola, J., Berraondo, P., Alfaro, M., Larrea, E., Prìeto, J., & Kramer, M. G. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.07.025 · Cited by 71
Chang, H., Jung, W., Kim, A., Kim, H. K., Kim, W. B., Kim, J. H., & Kim, B. (2017) · Apmis · doi:10.1111/apm.12703 · Cited by 70
Roth, G. S., & Decaens, T. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.10.010 · Cited by 70
Liu, F., Zeng, G., Zhou, S., He, X., Sun, N., Zhu, X., & Hu, A. (2018) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.01.018 · Cited by 70
Developments in cancer vaccines for hepatocellular carcinoma
Buonaguro, L. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1728-y · Cited by 67
CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside
Zhang, Q., Zhang, Z., Peng, M., Fu, S., Xue, Z., & Zhang, R. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1251539 · Cited by 66
Zhu, L., Li, N., Zhu, Q., Zhang, G., Han, Q., Zhang, P., Xun, M., Wang, Y., Zeng, X., Yang, C., et al. (2013) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2012.12.008 · Cited by 62
Zhang, X., Meng, Z., Qiu, S., Xu, Y. Y., Yang, D., Schlaak, J., Roggendorf, M., & Lu, M. (2009) · Cellular Microbiology · doi:10.1111/j.1462-5822.2009.01353.x · Cited by 61
Estevez, J., Chen, V. L., Podlaha, O., Li, B., Le, A. K., Vutien, P., Chang, E. T., Rosenberg‐Hasson, Y., Jiang, Z., Pflanz, S., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11975-7 · Cited by 59
CAR T-Cell Therapy in Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., & Go, W. Y. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1800913 · Cited by 58
GITR ligation enhances functionality of tumor‐infiltrating T cells in hepatocellular carcinoma
van Beek, A. A., Zhou, G., Doukas, M., Boor, P. P. C., Noordam, L., Mancham, S., Carrascosa, L. C., van der Heide‐Mulder, M., Polak, W. G., IJzermans, J. N. M., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32181 · Cited by 57
Kean, L. S., Turka, L. A., & Blazar, B. R. (2017) · Immunological Reviews · doi:10.1111/imr.12523 · Cited by 52
Mocan, T., Sparchez, Z. A., Crăciun, R., Bora, N., & Leucuta, D. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1975-4 · Cited by 52
Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model
Li, G., Liu, D., Cooper, T. K., Kimchi, E. T., Qi, X., Avella, D. M., Li, N., Yang, Q. X., KESTER, M. A., Rountree, C. B., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.044 · Cited by 51
Chae, Y. K., Galvez, C., Anker, J. F., Iams, W. T., & Bhave, M. A. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.12.004 · Cited by 51
Zhang, P., Shi, B., Gao, H., Jiang, H., Kong, J., Yan, J., Pan, X., Li, K., Zhang, P., Yao, M., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1497-4 · Cited by 49
Chen, M., Tabaczewski, P., Truscott, S. M., Kaer, L. V., & Stroynowski, I. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.2.1047 · Cited by 48
Chen, J., Ji, T., Zhao, J., Li, G., Zhang, J., Jin, R., Liu, J., Liu, X., Liang, X. H., Huang, D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8978 · Cited by 48
Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies
Hoseini, S. S., & Cheung, N. V. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.04.013 · Cited by 48
Sharma, S., Khosla, R., David, P., Rastogi, A., Vyas, A. K., Singh, D., Bhardwaj, A., Sahney, A., Maiwall, R., Sarin, S. K., et al. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00049 · Cited by 46
Biomarkers of immune tolerance in liver transplantation
Vionnet, J., & Fueyo, A. S. (2018) · Human Immunology · doi:10.1016/j.humimm.2018.02.010 · Cited by 46
Zhou, Z., Tong, D., Guan, J., Tan, H.-W., Zhao, L.-D., Zhu, Y., Yao, J., Yang, J., & Zhang, Z. (2016) · Europe PMC (PubMed Central) · Cited by 44
Sghaier, I., Mouelhi, L., Rabia, N. A., Alsaleh, B., Ghazoueni, E., Almawi, W. Y., & Loueslati, B. Y. (2016) · Cytokine · doi:10.1016/j.cyto.2016.10.004 · Cited by 44
Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside
Boisguérin, V., Castle, J. C., Löewer, M., Diekmann, J., Mueller, F., Britten, C. M., Kreiter, S., Türeci, Ö., & Şahin, U. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.820 · Cited by 43
Hepatitis-related hepatocellular carcinoma: Insights into cytokine gene polymorphisms
Dondeti, M. F., El‐maadawy, E. A., & Talaat, R. M. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i30.6800 · Cited by 43
Han, Y., Sun, F., Zhang, X., Wang, T., Jiang, J., Cai, J., Gao, Q., Hezam, K., Liu, Y., Xie, J., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02865-8 · Cited by 41
Wahl, C., Bochtler, P., Chen, L., Schirmbeck, R., & Reimann, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.05.076 · Cited by 40
Immunotherapy of Hepatocellular Carcinoma
Heinrich, B., Czauderna, C., & Marquardt, J. U. (2018) · Oncology Research and Treatment · doi:10.1159/000488916 · Cited by 40
Trojan, J., & Waidmann, O. (2016) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s112537 · Cited by 39
Iyer, R. V., Maguire, O., Kim, M., Curtin, L. I., Sexton, S., Fisher, D. T., Schihl, S. A., Fetterly, G. J., Menne, S., & Minderman, H. (2019) · Cancers · doi:10.3390/cancers11050681 · Cited by 39
Novel drugs in clinical development for hepatocellular carcinoma
Waidmann, O., & Trojan, J. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1058776 · Cited by 38
Novel immunotherapeutic approaches for hepatocellular carcinoma treatment
Busato, D., Mossenta, M., Baboçi, L., Cintio, F. D., Toffoli, G., & Bo, M. D. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1598859 · Cited by 38
Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors)
Bourke, J., O'Sullivan, M. D., & Khattak, M. A. (2016) · The Medical Journal of Australia · doi:10.5694/mja16.00586 · Cited by 35
Ma, X., Wang, S., Liu, S.-Y., Chen, K., Wu, Z., Li, D., Mi, Y.-T., Hu, L., Chen, Z., & Zhao, X. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i24.3030 · Cited by 34
Ramia, E., Chiaravalli, A. M., Eddine, F. B. N., Tedeschi, A., Sessa, F., Accolla, R. S., & Forlani, G. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1548243 · Cited by 33
Joerger, M., Güller, U., Bastian, S., Driessen, C., & von Moos, R. (2019) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.11.04 · Cited by 32
IL ‐17A promotes the invasion–metastasis cascade via the AKT pathway in hepatocellular carcinoma
Xu, Q., Yu, J., Guo, X., Hou, G., Yuan, S., Yang, Y., Yang, Y., Liu, H., Pan, Z., Yang, F., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12306 · Cited by 31
Harding, J. J. (2018) · Future Oncology · doi:10.2217/fon-2018-0008 · Cited by 30
Jiang, H., Zhao, Y., Song, Z., Green, M., Song, H., & Shao, Q. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.02.019 · Cited by 30
Ho, C., Chen, H., Hu, R., & Lee, P. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919843463 · Cited by 30
Natural killer cells in liver diseases
Zheng, M., Sun, H., & Tian, Z. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0621-4 · Cited by 26
TLS11a Aptamer/CD3 Antibody Anti-Tumor System for Liver Cancer
Hu, Z., He, J., Gong, W., Zhou, N., Zhou, S., Lai, Z., Zheng, R., Wang, Y., Yang, X., Yang, W. C., et al. (2018) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2018.2619 · Cited by 26
Metastatic Hepatocellular Carcinoma Responsive to Pembrolizumab
Truong, P. V., Rahal, A. K., & Kallail, K. J. (2016) · Cureus · doi:10.7759/cureus.631 · Cited by 24
Li, Y., Liu, Z., Li, Z., Wang, J., Yu, J., Yang, H., Chen, Z., & Tang, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010156 · Cited by 24
Using Frameshift Peptide Arrays for Cancer Neo-Antigens Screening
Zhang, J., Shen, L., & Johnston, S. A. (2018) · Scientific Reports · doi:10.1038/s41598-018-35673-0 · Cited by 20
Xu, Y., Li, H., Gao, R., Adeyemo, O., Itkin, M. G., & Kaplan, D. E. (2011) · Clinical Immunology · doi:10.1016/j.clim.2011.02.014 · Cited by 19
Fujinami, N., Yoshikawa, T., Sawada, Y., Shimomura, M., Iwama, T., Sugai, S., Kitano, S., Uemura, Y., & Nakatsura, T. (2016) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2016.02.010 · Cited by 16
From NAFLD to HCC: Is IL‐17 the crucial link?
Hatting, M., & Tacke, F. (2016) · Hepatology · doi:10.1002/hep.28934 · Cited by 14
Hedvat, M., Bonzon, C., Bernett, M. J., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-2784 · Cited by 9
Cited by
Pyroptosis: Mechanisms and Diseases
Yu, P., Zhang, X., Liu, N., Tang, L., Peng, C., & Chen, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00507-5 · Cited by 2,353
Metadata
- Authors
- Zongyi, Y., & Xiaowu, L.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 470
- Pages
- 8-17
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W2992211060
- Cited by
- 265
- References
- 167
- FWCI
- 12.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.